Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15765933 | 0.92 | KDM4E (0.54) | KDM4EATMCA2CALM1CYP19A1 | |
| SCHEMBL8107846 | 0.88 | KDM4E (0.58) | KDM4EATMPTGER3CA2 | |
| SCHEMBL23195552 | 0.86 | DRD2 (0.52) | KDM4EATMCA2CALM1 | |
| SCHEMBL13111718 | 0.86 | CA2 (0.52) | KDM4EATMCA2CALM1 | |
| SCHEMBL13634485 | 0.84 | L3MBTL1 (0.50) | KDM4EATMCA2CALM1 | |
| SCHEMBL5024579 | 0.84 | MAPT (0.50) | KDM4ECA2CALM1 | |
| SCHEMBL8373048 | 0.83 | KCNH2 (0.53) | KDM4ECA2CALM1 | |
| SCHEMBL2002631 | 0.83 | CA2 (0.48) | KDM4EATMCA2CALM1 | |
| SCHEMBL10459163 | 0.83 | CA2 (0.48) | KDM4EATMCA2CALM1 | |
| SCHEMBL89076 | 0.83 | CA2 (0.48) | KDM4EATMCA2CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168827-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8168827-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20090258900-A1 | AMIDE DERIVATIVE | AJINOMOTO CO. INC (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090258900-A1 | AMIDE DERIVATIVE | AJINOMOTO CO. INC (JP) | 2009-10-15 | — | — | US | disclosed |
| US-7572815-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7572815-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258900-A1 | AMIDE DERIVATIVE | NR0B1, NR0B2, NR1I3 | KDM4E 2426/4885ATM 3808/4885PTGER3 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.